The historic chambers of Gray’s Inn hosted a gathering of St John’s College alumni on 29 September, where three seasoned founders unpacked the current state of biotech and healthtech. Moderated by Professor Jean Abraham, a leading voice in precision breast-cancer medicine at Cambridge, the discussion blended personal narratives with forward-looking industry analysis.
The panel at Gray’s Inn: key players and their journeys
John Bogassian, a 2011 graduate, arrived with a dual résumé: co-founder of Pangea Bio and current CEO of Kadence Bio. His story highlighted the transition from academic research to commercial pipelines, emphasizing the necessity of early-stage validation before scaling. Lisa Anson, class of 1986, narrated the evolution of RedX from a modest research group into a clinical-stage biotech, stressing that “failure in science is part of the process of innovation”. Jonathan O’Keeffe, also a 2011 alumnus, described how Machine Medicine Technologies leverages data-driven platforms to re-engineer therapeutic delivery.
Each speaker underscored a common thread: an unwavering focus on unmet healthcare needs. Whether it was designing novel gene-editing tools or creating modular diagnostic kits, they all stressed that the initial insight must stem from a clear patient problem, not from technology for its own sake.
Emerging tech trends: AI beyond drug discovery
The conversation quickly gravitated toward the expanding footprint of artificial intelligence in life sciences. Lisa Anson noted that AI excels at crunching massive datasets, yet the true inventor remains human, because algorithms can only recombine existing information. She argued that creative hypothesis-generation is still a distinctly human skill, and AI serves as an accelerator rather than a replacement.
Beyond identifying molecular candidates, panelists described AI’s role in streamlining clinical trials. By predicting patient stratification and optimizing protocol design, algorithms can reduce trial size and duration, translating into lower costs and faster market entry. Jonathan O’Keeffe added that predictive models now inform real-time enrollment decisions, turning traditionally rigid trials into adaptive, data-rich experiments.
These advances, however, come with regulatory and ethical hurdles. The speakers warned that while AI can propose dose-adjustments or flag safety signals, ultimate responsibility still lies with clinicians and regulatory bodies, necessitating transparent validation pipelines.
Fundraising tactics from the frontlines
Securing capital emerged as a separate art form. Jonathan O’Keeffe revealed a provocative mantra: “turn fear into greed”. By framing the problem as an urgent market gap, founders can make investors feel they might miss a lucrative opportunity if they don’t act. This psychological lever, he explained, turns hesitation into urgency.
John Bogassian echoed this sentiment, emphasizing the need to present a compelling value proposition that makes investors feel they are acquiring a “great deal”. He advised startups to balance bold vision with concrete milestones, demonstrating both ambition and feasibility.
Lisa Anson added a personal note on resilience: “If you can’t go through the door, go through the window.” She highlighted that setbacks—whether scientific dead-ends or financing rejections—are inevitable. Persistence, she argued, is the differentiator between ventures that dissolve and those that ultimately succeed.
Reflections on the St John’s experience
When prompted by Professor Abraham to reflect on their university years, each panelist highlighted the freedom St John’s afforded them to explore diverse interests. This interdisciplinary exposure, they agreed, cultivated the confidence to navigate ambiguous problems and to speak fluently across scientific, commercial, and regulatory domains.
In sum, the Gray’s Inn session painted a vivid picture of a sector where human creativity intertwines with cutting-edge AI tools where resilience fuels financing breakthroughs, and where a liberal arts foundation can still propel deep-tech ventures. Attendees left with actionable takeaways and a renewed belief that the next wave of medical breakthroughs will be born from the same blend of curiosity, data, and determination.
